文献速递淋巴瘤

弥漫大B细胞淋巴瘤晚期复发:利妥昔单抗对发生率与结局的影响

Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their incidence and outcome.
PubMed 文献 · Br J Haematol · 2019-08-05

该研究分析1113例弥漫大B细胞淋巴瘤(DLBCL)患者,196例首次完全缓解后复发者中36例(占复发18%、全部DLBCL的3%)为诊断后5年以上晚期复发。晚期复发者初诊风险特征更佳,利妥昔单抗一线治疗降低晚期复发风险,复发后病因特异性生存优于早期复发者。

要点

  • 晚期复发占复发的18%、全部DLBCL的3%。
  • 晚期复发者初诊LDH正常、Ann Arbor早期、IPI低。
  • 利妥昔单抗一线治疗降低晚期复发风险(P<0·001)。

核心结论

  • DLBCL晚期复发(诊断后>5年)占复发的18%、全部DLBCL的3%,其初诊风险特征更佳且复发后病因特异性生存优于早期复发者。
  • 利妥昔单抗纳入一线治疗可降低晚期复发风险(P<0·001)。

研究设计与样本

  • 回顾性分析1113例DLBCL患者数据,其中196例首次完全缓解后复发,36例为诊断后5年以上晚期复发。

主要发现

  • 196例复发患者中36例(18%的复发、3%的全部DLBCL)为诊断后5年以上晚期复发。
  • 与早期复发者相比,晚期复发者初诊时LDH正常(P=0·002)、Ann Arbor分期早(P=0·006)、IPI低(P=0·003)。
  • 利妥昔单抗一线治疗降低晚期复发风险(P<0·001)。
  • 复发后5年病因特异性生存率晚期复发者53%、早期复发者31%(P=0·033)。
  • 复发后5年总生存率晚期复发者47%、早期复发者25%(P=0·054)。

临床怎么用

  • 对DLBCL完成一线治疗后长期缓解者仍需关注晚期复发可能,尤其初诊高危特征者。
  • 晚期复发者复发后治疗结局相对较好,可据此进行预后沟通与治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse large B-cell lymphoma (DLBCL) constitutes 25-35% of all non-Hodgkin lymphomas in Western countries. Approximately two thirds of the patients can be cured with standard immuno-chemotherapy. Most relapses occur within 1-2 years from diagnosis, however, the occurrence of relapses after 5 years or more has been described. We aimed at defining the incidence and clinical features of late relapses. Data of 1113 DLBCL patients were analysed. Among the 196 patients relapsing after a first complete remission, 36 (18% of relapses and 3% of all DLBCLs) experienced a recurrence more than 5 years from diagnosis. Late relapsing patients, in comparison with those relapsing earlier, showed a more favourable risk profile at presentation: normal lactate dehydrogenase levels (P = 0·002), early Ann Arbor stage (P = 0·006) and low International Prognostic Index (P = 0·003). The risk of late relapse was lowered by the introduction of rituximab as part of the front-line treatment (P < 0·001). Cause-specific survival (CSS) from the time of relapse was significantly better for late relapsing patients compared to those relapsing early: 5-year CSS rates were 53% and 31%, respectively (P = 0·033). A trend toward a better overall survival was also observed, with 5-year rates after relapse of 47% and 25%, respectively (P = 0·054).

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Vannata B, Conconi A, Winkler J, et al. Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their incidence and outcome. Br J Haematol. 2019. PMID: 31385291. doi:10.1111/bjh.16106

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。